Eli Lilly and Company is a leading global US pharmaceutical company dedicated to discovering, developing, and manufacturing innovative medicines. Focusing on diabetes, oncology, immunology, and neuroscience, Lilly improves patient health worldwide through scientific research and advanced therapies.
Date confirmed from the company's own financial calendar.
Pre-market — typically before 3:30 p.m. German time (before the US open at 9:30 a.m. New York time).
Eli Lilly and Company (LLY) released its Q2 2026 financial results on August 5, 2026, before the market open. The reported earnings per share (EPS) of 8.38 USD beat the analyst estimate of 6.40 USD by 30.9%. Revenue for the quarter was 22974 million USD. The stock price reacted to the release with an increase of 4.86%.
Generated automatically from our data — as of 08/12/2026 Read the article →
Eli Lilly and Company is scheduled to report its next quarterly earnings on 10/29/2026. Pre-market — typically before 3:30 p.m. German time (before the US open at 9:30 a.m. New York time).
Eli Lilly and Company last reported quarterly earnings on 8/5/2026 (Q2 2026). Earnings per share (EPS) came in at 8.38 USD.
Across its last 5 earnings reports, Eli Lilly and Company stock moved by ±6.4% on average the following day. The largest reaction was +10.3% on 02/04/2026; 5 of 5 reactions were positive.
Eli Lilly and Company has beaten analyst EPS estimates in 5 of its last 5 evaluated quarters (beat rate: 100%).
Use the 'Subscribe in calendar' button on this page to add all dates to Google Calendar, Apple Calendar or Outlook. Dates update automatically when they change.
Basis: price reactions to the last 5 report dates (close to close).
Basis: 5 quarters with an analyst estimate and reported EPS.
Past price reactions are not a reliable indicator of future performance.